Ginseng Leaf Extract Prevents High Fat Diet-Induced Hyperglycemia and Hyperlipidemia through AMPK Activation

Hai-Dan Yuan, Sung-Jip Kim, Hai-Yan Quan, Bo Huang, and Sung-Hyun Chung*
Department of Life and Nanopharmaceutical Science, Kyung Hee University College of Pharmacy, Seoul 130-701, Korea

This study evaluated the protective effects of ginseng leaf extract (GLE) against high fat-diet-induced hyperglycemia and hyperlipidemia, and explored the potential mechanism underlying these effects in C57BL/6J mice. The mice were randomly divided into four groups: normal control, high fat diet control (HFD), GLE-treated at 250 mg/kg, and GLE-treated at 500 mg/kg. To induce hyperglycemic and hyperlipidemic states, mice were fed a high fat diet for 6 weeks and then administered GLE once daily for 8 weeks. At the end of the treatment, we examined the effects of GLE on plasma glucose, lipid levels, and the expression of genes related to lipogenesis, lipolysis, and gluconeogenesis. Both GLE groups lowered levels of plasma glucose, insulin, triglycerides, total cholesterol, and non-esterified fatty acids when compared to those in HFD group. Histological analysis revealed significantly fewer lipid droplets in the livers of GLE-treated mice compared with HFD mice. To elucidate the mechanism, Western blots and RT-PCR were performed using liver tissue. Compared with HFD mice, GLE-treated mice showed higher levels of phosphorylation of AMP-activated protein kinase (AMPK) and its substrate, acetyl-CoA carboxylase, but no differences in the expression of lipogenic genes such as sterol regulatory element-binding protein 1a, fatty acid synthase, sterol-CoA desaturase 1 and glycerol-3-phosphate acyltransferase. However, the expression levels of lipolysis and fatty acid uptake genes such as peroxisome proliferator-activated receptor-α and CD36 were increased. In addition, phosphoenolpyruvate carboxykinase gene expression was decreased. These results suggest that GLE ameliorates hyperglycemia and hyperlipidemia by inhibiting gluconeogenesis and stimulating lipolysis, respectively, via AMPK activation.

Keywords: Ginseng leaf extract, High fat diet, AMP, C57BL/6J mice

INTRODUCTION

Diabetes mellitus is a common endocrine disease characterized by hyperglycemia and long-term complications affecting the eyes, kidneys, nerves, and blood vessels [1,2]. At present, there are more than 194 million people with diabetes worldwide [3], and this number is estimated to increase to 333 million by 2025 [4]. The management of diabetes is considered a global problem, and a cure has yet been discovered. Anti-diabetic drugs such as insulin, biguanides, sulphonylureas, and alpha glucosidase inhibitors are currently used to treat diabetest. However, these drugs are associated with many side effects including obesity, osteoporosis sodium retention, hypoglycemia, and lactic acidosis [5-8]. To avoid such adverse side effects, many natural plants have been investigated recently as possible treatments to prevent and improve diabetes [9-11].

Ginseng, well-known medicinal plant, is widely used as an extremely valuable treatment in Oriental societies. The pharmacological effects of ginseng are attributable mainly to the ginsenosides in the plant, and many stud-
ies have documented the anti-hyperglycemic and anti-
hyperlipidemic activities of ginsenosides [12-17]. To
date, more than 60 ginsenosides have been identified
in different parts of the ginseng plant, and extracts of
ginseng roots, rootlets, berries, and leaves have shown
pharmacological activities such as islet protection, insu-
lin sensitization, and anti-hyperglycemia, anti-obesity,
and antioxidant effects [18-23].

AMP-activated protein kinase (AMPK) is a serine-
threonine kinase that is activated following a rise in the
intercellular AMP:ATP ratio [24]. Recently, AMPK has
emerged as an attractive target molecule for the treat-
ment of metabolic disorders, including obesity and type
2 diabetes [25]. The amelioration of hyperglycemia and
hyperlipidemia by several flavonoids is thought to be
mediated via AMPK activation [26,27]. However, it
is not known whether the beneficial effects of the gin-
seng leaf on high fat diet-induced hyperglycemia and
hyperlipidemia are attributable to AMPK activation.
Here, we investigated the anti-hyperglycemic and anti-
hyperlipidemic effects of ginseng leaf and the potential
mechanisms underlying these actions in C57BL/6J mice
fed a high fat diet.

MATERIALS AND METHODS

Preparation of ginseng leaf extract

Ginseng leaves were dried in the shade for 1 week and
extracted by boiling in 70% ethanol for 5 h. The solution
(ginseng leaf extract, GLE) was filtered and evaporated
under vacuum to obtain a powder.

Animals and diets

Six-week-old C57BL/6J mice were purchased from
Orient Bio (Seoul, Korea) and acclimatized to the labo-

ratory environment for 1 week before the experiment.
The mice were allowed free access to water and food
and were housed under conditions of constant room
temperature (22±2°C) and humidity (50±10%) with an
automatic 12 h light:12 h dark cycle. The experimental
protocol was approved by the Institutional Animal Eth-
sics Committee of Kyung Hee University. The mice were
randomly divided into four groups of six mice each:
normal control (Con), high fat diet (HFD), HFD+GLE
at 250 mg/kg (G250), and HFD+GLE at 500 mg/kg
(G500). Control mice were allowed free access to the
regular diet (Con) or HFD. In the GLE-treated groups,
mice were allowed free access to a HFD for 6 weeks
and were then orally administered GLE once daily for 8
weeks. The composition of the experimental diet (Table
1) was based on the HFD 45% cal semi-synthetic diet.
Body weight was measured once a week during the ex-
periment.

Determination of serum parameters

At the end of the experimental period, blood samples
were collected and the levels of plasma glucose, insulin,
triglycerides (TG), total cholesterol (TC), non-esterified
fatty acids (NEFA), and leptin were measured. Plasma
glucose concentrations were determined using the glu-
cose oxidase method (Asan Pharmaceutical Co., Seoul,
Korea); plasma insulin concentrations, using a mouse
insulin enzyme immunoassay kit (Sibayagi, Gunma,
Japan); plasma TG and TC concentrations, using com-
mercially available kits (Asan Pharmaceutical); plasma
NEFA levels, using the enzymatic colorimetric method
(Eiken, Tokyo, Japan); and leptin levels, using a mouse
leptin enzyme immunoassay kit (Linco Research, St.
Charles, MO, USA).

Histological analysis

Liver tissue was fixed in 10% neutral-buffered for-
malin, embedded in paraffin, and sectioned at a 5 μm
thickness (Leica, Wetzlar, Germany). The sections were
stained with hematoxylin-eosin for microscopic assess-
Western blot analysis

After the mice were sacrificed, the liver was immediately removed, instantly soaked in liquid nitrogen, and stored at -70°C. Protein extracts were prepared using a protein extraction kit (Intron Biotechnology Inc., Seoul, Korea). Lysates (40 μg) were electrophoresed in an 8% SDS-polyacrylamide gel, and the separated proteins were electroblotted onto a nitrocellulose membrane. The membrane was incubated for 1 hr at room temperature in a blocking solution of Tris-buffered saline plus Tween 20 (TBST) containing 5% skim milk (w/v), followed by incubation overnight at 4°C with a 1:2,000 dilution of antibody against AMPK, phospho-AMPK, acetyl-CoA carboxylase (ACC), phospho-ACC (Cell Signaling, Beverly, MO, USA), or β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After four washes in 0.1% TBST, the membrane was incubated with a 1:3,000 dilution of horseradish peroxidase-conjugated goat anti-rabbit IgG or donkey anti-rabbit IgG antibody (Santa Cruz Biotechnology) for 1 hr at room temperature. The membrane was washed four times in TBST, and immunoreactive protein bands were visualized by enhanced chemiluminescence (Amersham, Uppsala, Sweden).

RNA preparation and RT-PCR

Total mRNA was isolated from mouse livers using an Easy-Blue kit (Intron Biotechnology) according to the manufacturer’s instructions. From each sample, total RNA (10 μg) from each sample was reverse transcribed into cDNA using Moloney murine leukemia virus transcriptase and oligo(dT)15 primer (Promega, Madison, WI, USA). PCR was performed using the following specific sense and anti-sense primer sets: sterol regulatory element-binding protein 1a (SREBP1a), 5′-CGG CTA CCG TTC TGC TAT CA-3′ and 5′-TGC TGC CAA AAG ACA AGG G-3′; fatty acid synthase (FAS), 5′-GAT CCT GGA ACG AGA ACA C-3′ and 5′-AGA CTG TGG AAC ACG GTG GT-3′; sterol-CoA desaturase 1 (SCD1), 5′-CGA GGG TTG GTT GTT GAT CTG T-3′ and 5′-ATA GCA CTG TTG GCC CTG GA-3′; glycerol-3-phosphate acyltransferase (GPAT), 5′-GGT AGT GGA TAC TCT GTC TGT CA-3′ and 5′-CAT CAG CAA CAT CAT TCG GT-3′; peroxisome proliferator-activated receptor-α (PPAR-α), 5′-CCC TGA ACA TCG AGT GTC GA-3′ and 5′-CTT GCC CAG AGA TTG GAC ATT TGC AGG TCT ATC-3′ and 5′-GTG AAT CCA GGT ATG GGT TCC AC-3′; phosphoenolpyruvate carboxykinase (PEPCK), 5′-ATG CCT CTT CAG CTG CAT A-3′ and 5′-TTA CAT CTG GCT GAT TCT CTT TT-3′; and cyclophilin (CPN), 5′-ATG GTC AAC CCC ACC GTG-3′ and 5′-TTA GAG TAC GGG GTG G-3′. CPN was amplified as a control gene. PCR was performed at 95°C for 5min, 95°C for 30 sec, 57°C for 30 sec, 72°C for 30 sec, and amplified for 30 cycles. PCR was performed at of 95°C for 30 s; 51°C (CD36), 55°C (SREBP1a, FAS, PPAR-α, PEPCK, CPN), or 57°C (SCD1, GPAT) for 30 s; and 72°C for 1 min, with a final extension at 72°C for 10 min. The PCR products were electrophoresed in a 1% agarose gel and visualized by ethidium bromide staining (0.5 μg/mL). Scanning densitometry was performed with an I-MAX gel image analysis system (Core-Bio, Seoul, Korea).

Statistical analysis

The results are expressed as means±SEM. Differences between groups were analyzed using Student’s t-test. Statistical significance was considered for p<0.05.

RESULTS

Effects on body weight and food intake

Table 2 shows the effects of GLE on body weight gain, food intake, and feed efficiency in HFD-induced obese mice treated for 8 weeks. Compared with the HFD control group, the G250 and G500 groups had 3.27% and 2.35% reductions in initial body weight, respectively, compared to the HFD group. The final body weight of the G250 and G500 groups was also lower than that of the HFD group. The body weight gain of the G250 and G500 groups was significantly lower than that of the HFD group. The food intake of the G250 and G500 groups was also significantly lower than that of the HFD group. The feed efficiency of the G250 and G500 groups was significantly higher than that of the HFD group.

| Table 2. Effects of ginseng leaf extract on body weight and food intake |
|-----------------|---------|---------|---------|---------|
|                 | Con     | HFD     | G250    | G500    |
| Initial body weight (g) | 22.5±0.6 | 22.2±0.3 | 21.8±0.5 | 22.0±0.2 |
| Final body weight (g)    | 27.3±0.3 | 33.6±0.8 | 32.5±0.5 | 31.3±0.5 |
| Body weight gain (g)     | 4.8±0.3  | 11.5±0.6 | 10.7±0.7 | 9.3±0.5  |
| Food intake (g/mouse)    | 242.1    | 241.2    | 241.2    | 234.9    |
| Feed efficiency          | 0.020±0.004 | 0.048±0.006 | 0.044±0.003 | 0.039±0.006 |

Values represent the mean±SE (n=6).

*p<0.001 vs. Con.

*p<0.05 vs. HFD.
6.85% lower final body weights ($p<0.05$), respectively. The G500 group also showed lower food intake and significantly decreased feeding efficiency ($p<0.05$) as compared with the HFD group.

**Effects on metabolic parameters**

Table 3 shows the effects of GLE on metabolic parameters in HFD-induced obese mice. Plasma glucose levels were significant decreased by 18.2% ($p<0.01$) and 22.6% ($p<0.01$) in the G250 and G500 groups, respectively, compared with the level in the HFD control group, and plasma insulin levels were 51.7% ($p<0.001$) and 52.9% ($p<0.001$) lower in the G250 and G500 groups as compared with the HFD control. The lower plasma glucose and insulin levels resulted in markedly lower insulin resistance index (HOMA-IR) values in the GLE-treated groups as compared with the HFD control, 60.9% lower ($p<0.001$) in the G250 group and 63.6% lower ($p<0.001$) in the G500 group. The plasma TG, TC, and NEFA levels were significantly lower, by 30.5% ($p<0.001$), 17.8% ($p<0.001$), and 36.8% ($p<0.001$), respectively, in the G500 group as compared with the HFD group.

**Histological observations**

Histological analysis revealed significantly fewer lipid droplets in the livers from GLE-treated mice than in the HFD control livers (Fig. 1A).

**Effect on AMPK activation**

AMPK plays a key role in regulating carbohydrate and lipid metabolism and a potential therapeutic target for treatment of metabolic diseases [28]. The activation of hepatic AMPK leads to increased fatty acid oxidation and ketogenesis along with the simultaneous inhibition of hepatic fatty acids, TG, lipogenesis, cholesterol synthesis, and glucose production [28-31]. We examined whether GLE activates AMPK via phosphorylation in the liver. As shown in Fig. 1B, GLE-treated mice had significantly higher levels of phosphorylated AMPK and ACC than HFD control mice.

**Effects on gene expression related to lipogenesis, lipolysis, and gluconeogenesis**

The expression of genes involved in lipogenesis, lipolysis and gluconeogenesis were examined by RT-PCR. As shown in Fig. 1C, GLE did not affect the expressions of SREBP1a, FAS, SCD1, and GPAT, which are all associated with TG synthesis (Fig. 1C). However, the expression levels of the fatty acid transport protein CD36 gene and the lipolysis-related PPAR-α gene were increased in GLE-treated mice. In addition, the expression of PEPCK, a rate-limiting enzyme of the gluconeogenesis pathway, was decreased in GLE-treated mice as compared with the HFD control mice.

**DISCUSSION**

Ginseng is a well-known medicinal plant that has been used in traditional oriental medicine for several thousand years. In traditional Chinese medicine, ginseng root has been used more often than other plant parts; however, it is quite costly. Other parts of the ginseng plant such as berries and leaves could be harvested along with the root to yield additional herbal material and to improve the cost-effectiveness of ginseng cultivation [32]. However, one issue of concern regarding the use of ginseng as a therapeutic agent is its marginal anti-diabetic effects compared with commercially available oral hypoglycemics. To develop a more efficacious anti-diabetic agent from ginseng, GLE was considered. GLE has recently been reported to possess hypoglycemic activity [32,33],

**Table 3. Effects of ginseng leaf extract on metabolic parameters in blood**

<table>
<thead>
<tr>
<th></th>
<th>Con</th>
<th>HFD</th>
<th>G250</th>
<th>G500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood glucose (mM)</td>
<td>15.7±0.5</td>
<td>21.5±0.5</td>
<td>19.0±0.9</td>
<td>17.7±0.5</td>
</tr>
<tr>
<td>Insulin (U/mL)</td>
<td>60.2±12.3</td>
<td>235.6±34.1</td>
<td>113.9±14.1</td>
<td>119.9±13.8</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>42.3±8.9</td>
<td>223.7±30.8</td>
<td>98.2±16.2</td>
<td>87.5±10.9</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>50.1±3.3</td>
<td>87.1±3.7</td>
<td>67.3±3.5</td>
<td>60.5±2.5</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>120.3±4.7</td>
<td>188.2±2.7</td>
<td>161.3±4.1</td>
<td>154.7±2.5</td>
</tr>
<tr>
<td>Leptin (ng/mL)</td>
<td>2.1±0.3</td>
<td>13.7±1.6</td>
<td>13.8±0.9</td>
<td>11.4±1.1</td>
</tr>
<tr>
<td>NEFA (μEq/L)</td>
<td>1151.2±63.0</td>
<td>1700.2±62.9</td>
<td>1048.8±46.4</td>
<td>1074.0±61.2</td>
</tr>
</tbody>
</table>

Values represent the mean±SE ($n=6$). Plasma parameters were analyzed in plasma samples obtained from blood of 12 hr fasted mice. Homeostasis Model Assessment was used to calculate an index of insulin resistance as insulin (U/mL) x glucose (mM)/22.5.

1) $p<0.01$, $p<0.001$ vs. Con.
2) $p<0.05$, $p<0.01$, $p<0.001$ vs. HFD.
although the mechanisms underlying its beneficial effects on high fat diet-induced diabetes have not been identified. In the present study, we investigated the protective effects of GLE against HFD-induced hyperglycemia in C57Bl/6J mice and found that GLE prevented HFD-induced diabetes via AMPK activation.

Obesity is a well-recognized risk factor for type 2 diabetes, especially when combined with other known risk factors, and reduction of the risk for type 2 diabetes through weight management has been an important therapeutic goal. In the present study, GLE prevented body weight gain and significantly decreased plasma glucose and insulin levels in HFD-induced obese mice. As a result of decreased plasma glucose and insulin levels, the HOMA-IR values in the GLE groups were also significantly decreased as compared with the value in the HFD group. In addition, the levels of plasma TG, TC, NEFA, and leptin were all significantly lower in the GLE-treated group than in the HFD group. These results suggest that GLE may have beneficial effects on improving insulin resistance and hyperlipidemia induced by HFD. Histological analysis revealed a significantly lower number of lipid droplets in the livers from GLE-treated mice as compared with HFD mice (Fig. 1A). Taken together, these results demonstrate that GLE has strong effects on obesity-related hyperglycemia and hyperlipidemia.

AMPK is a heterotrimeric serine/threonine kinase that is widely expressed in a variety of organs, including the liver. Numerous studies have described the effects of AMPK activation on liver metabolism [34,35]. Two of
the classical therapeutic targets of the system are ACC and 3-hydroxy-3-methylglutaryl-CoA reductase, which catalyze the key regulatory steps in fatty acid and sterol synthesis, respectively. The overall effects of AMPK activation in the liver include decreases in fatty acid, triglyceride, and sterol synthesis, and increases in fatty acid oxidation and ketogenesis [29-31]. In the present study, higher levels of phosphorylated AMPK and ACC were seen in GLE-treated mice as compared with HFD control mice. This result may elucidate the mechanism by which GLE promotes fatty acid oxidation and inhibits TG accumulation, thus enhancing insulin sensitivity.

It has been reported that AMPK improves a decreased ATP:AMP ratio [24]. When AMPK is activated, it inhibits lipogenic enzymes through the inhibition of SREBP1 transcriptional activity [36]. Numerous studies have indicated that SREBP1s play a key role in triglyceride synthesis by regulating lipogenesis genes such as FAS, SCD1, and GPAT. Moreover, lipolysis genes such as PPAR-α and CD36 also participate fatty acid oxidation [30,37]. In the present study, GLE did not affect the expression of SREBP1α, FAS, SCD1, and GPAT, which are all associated with TG synthesis, whereas it increased the expression of the fatty acid uptake- lipolysis-related genes CD36 and PPAR-α. Interestingly, the expression of PEPCCK, a rate-limiting enzyme in the gluconeogenesis pathway, was markedly decreased in GEL-treated mice as compared with the HFD control mice. Based on these results, we conclude that GLE stimulated fatty acid β-oxidation via AMPK activation and ACC inactivation, and increased the expression of genes associated with lipolysis (i.e., CD36, PPAR-α), thereby stimulating fatty acid oxidation and decreased triglyceride content in the liver. Furthermore, through AMPK activation, GLE reduced hepatic glucose production by inhibiting PEPCCK expression. As a result, GLE intercepted triglyceride amassment and ameliorated the insulin resistant status, subsequently decreasing fasting glucose levels.

In summary, we conclude that GLE prevents HFD-induced hyperglycemia and hyperlipidemia via AMPK activation in C57BL/6J mice and that GLE may be a potential therapeutic agent for type 2 diabetes or dyslipidemia.

ACKNOWLEDGEMENTS

This work was supported by a grant from the Kyung Hee University post-doctoral fellowship in 2010 (KHU-20100424).

REFERENCES

13. Park MW, Ha J, Chung SH. 20(S)-ginsenoside Rg3, en-
hances glucose-stimulated insulin secretion and activates AMPK. Biol Pharm Bull 2008;31:748-751.